COR: the cashflow

MyFinsight

For the year ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Net income	1,567,814	1,519,273	1,732,576	1,666,540
Depreciation, including amounts charged to cost of goods sold	501,310	448,200	418,830	390,643
Amortization, including amounts charged to interest expense	567,106	670,642	562,018	319,192
Provision for credit losses	63,306	40,834	54,389	26,053
Provision (benefit) for deferred income taxes	59,864	-102,324	-118,864	196,184
Share-based compensation expense	147,963	147,998	124,624	93,400
Lifo (credit) expense	-76,875	-52,168	204,595	67,171
Impairment of assets, including goodwill	837,378	418,000	0	80,882
Loss (gain) on divestiture of businesses	-35,539	0	40,665	56,228
Turkey highly inflationary impact	55,519	55,309	95,938	-
Adjustments-Contingent Consideration Equity Units	121,666	-	-	-
Turkey highly inflationary impact	-	-	-	51,966
Adjustments-Contingent Consideration Predefined Business Objective	19,550	-	-	-
Gain on remeasurement of equity investment	-	-	-	4,834
(gain) loss on remeasurement of equity investment	14,058	-16,201	242	-
Loss on early retirement of debt	-	-	-	0
Gain on divestiture of equity investment	12,838	-	-	-
Other, net	33,548	-24,032	-3,593	-11,781
Accounts receivable	1,923,411	2,784,339	2,711,786	1,659,525
Inventories	1,269,429	1,479,599	2,183,368	665,370
Income tax receivable	-	11,109	-102,201	-49,307
Prepaid expenses and other assets	-173,857	-167,781	-109,041	-102,708
Accounts payable	3,693,364	4,968,093	6,103,451	3,320,725
Accrued expenses	-21,131	148,533	51,112	-457,233
Income taxes payable and other liabilities	-213,724	-204,517	-196,146	-330,079
Long-term accrued litigation liability	-404,102	-506,155	-399,963	-500,195
Net cash provided by operating activities	3,875,120	3,484,685	3,911,334	2,703,088
Capital expenditures	667,981	487,173	458,359	496,318
Cost of acquired companies, net of cash acquired	4,095,630	69,771	1,409,835	133,814
Cost of equity investments	196,242	30,430	743,275	18,491
Proceeds from sale of property and equipment	-	-	-	6,302
Non-customer note receivable	34,814	50,000	-	-
Proceeds from divestiture of businesses	-	0	0	272,586
Other, net	-17,374	-19,278	-9,004	-1,298
Net cash used in investing activities	-4,977,293	-618,096	-2,602,465	-368,437
Senior notes and loan borrowings	4,508,482	688,321	157,547	155,189
Senior notes and other loan repayments	-	662,525	811,353	1,238,954
Senior notes and loan repayments	1,280,615	-	-	-
Borrowings under revolving and securitization credit facilities	132,134,224	69,703,045	78,218,439	4,832,605
Repayments under revolving and securitization credit facilities	132,166,423	70,114,293	78,187,891	4,671,943
Payment of premium on early retirement of debt	-	-	-	0
Purchases of common stock	435,471	1,491,367	1,180,728	483,704
Exercises of stock options	29,133	37,840	61,152	93,912
Cash dividends on common stock	437,081	416,168	398,752	391,687
Profarma retail equity offering	-	-	-	0
Employee tax withholdings related to restricted share vesting	77,783	63,500	71,279	38,076
Other, net	-25,352	-12,347	-9,413	-10,122
Net cash provided by (used in) financing activities	2,249,114	-2,330,994	-2,222,278	-1,752,780
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	-50,272	9,396	72,759	-57,850
Increase (decrease) in cash, cash equivalents, and restricted cash, including cash classified within assets held for sale	-	544,991	-840,650	524,021
Less increase in cash classified within assets held for sale	-	0	0	-610
Increase (decrease) in cash and cash equivalents	1,096,669	544,991	-840,650	523,411
Cash and cash equivalents at beginning of period	3,297,880	2,752,889	3,593,539	3,070,128
Cash and cash equivalents at end of period	4,394,549	3,297,880	2,752,889	3,593,539

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

COR: the cashflow